| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 8711765 | Annals of Allergy, Asthma & Immunology | 2018 | 7 Pages | 
Abstract
												Alternative strategies that might improve pediatric asthma management and control include replacement of short-acting β2-agonist relievers by an inhaled corticosteroid plus a fast-acting β2-agonist (short-acting β2-agonist or fast- and long-acting β2-agonist) combination at Global Initiative for Asthma step 1 or 2 to ensure that patients receive an inhaled corticosteroid whenever they feel the need for symptomatic relief. Such an approach could eliminate the problem of learned overuse or over-reliance on short-acting β2-agonist reliever medication and address the other challenges in current pediatric asthma management. Clinical studies in pediatric patients or large studies involving a proportion of pediatric patients are required to provide the supporting evidence needed to help advance such new approaches and improve asthma control from a pediatric perspective.
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Dermatology
												
											Authors
												Stanley J. MD, Bradley MD, 
											